Mandate

Vinge acted as local counsel in relation to the sale of Phadia, the biotechnology company, for SEK 22 billion

May 20, 2011

Cinven has entered into an agreement with Thermo Fisher Scientific to sell the Uppsala based biotechnology company, Phadia Group, for SEK 22 billion. Phardia is a spin-off from the former Pharmacia and enjoys a leading position within allergy testing.

Vinge acted as local counsel advising on Swedish legal issues for Cinven/Freshfields. Vinge's team consisted of partner Christina Kokko and associates Joacim Rydergård, Jonas Bergström, Alex Miller and Albert Wållgren.

Related

Vinge advises Stockwik Förvaltning in conjunction with the acquisition of Labino

Vinge has advised Stockwik Förvaltning in connection with its acquisition of Labino, a world-leading Swedish manufacturer of industrial UV light fixtures.
December 19, 2025

Vinge advises Revivo Group in conjunction with the acquisition of Nordisk Ytbehandling

Vinge has advised Revivo Group in connection with the acquisition of Nordisk Ytbehandling, a well-established contracting company based in Nyköping specialising in blasting as well as anti-corrosion and fire protection painting, with a solid customer base within the industrial and infrastructure sectors.
December 19, 2025

Vinge advises on the sale of NCS Colour

Vinge has advised Sobro and other owners in conjunction with Helix Kapital becoming a new owner partner in NCS Colour, together with the management team.
December 19, 2025